OVID [NASD]
Ovid Therapeutics Inc.
Index- P/E- EPS (ttm)-0.99 Insider Own23.37% Shs Outstand70.35M Perf Week-15.53%
Market Cap123.19M Forward P/E- EPS next Y-1.04 Insider Trans0.00% Shs Float53.96M Perf Month-37.86%
Income-67.50M PEG- EPS next Q-0.25 Inst Own52.60% Short Float1.16% Perf Quarter-48.67%
Sales1.40M P/S87.99 EPS this Y227.00% Inst Trans3.16% Short Ratio3.93 Perf Half Y-46.63%
Book/sh2.35 P/B0.74 EPS next Y30.10% ROA- Target Price4.70 Perf Year-58.07%
Cash/sh2.35 P/C0.74 EPS next 5Y- ROE- 52W Range1.75 - 4.80 Perf YTD-45.79%
Dividend- P/FCF- EPS past 5Y31.50% ROI68.40% 52W High-63.75% Beta1.62
Dividend %- Quick Ratio16.60 Sales past 5Y- Gross Margin- 52W Low-0.57% ATR0.13
Employees49 Current Ratio16.60 Sales Q/Q-99.30% Oper. Margin- RSI (14)15.45 Volatility6.55% 6.24%
OptionableYes Debt/Eq0.00 EPS Q/Q-109.10% Profit Margin- Rel Volume1.82 Prev Close1.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume159.22K Price1.74
Recom1.70 SMA20-27.37% SMA50-38.82% SMA200-46.02% Volume290,235 Change-0.57%
Apr-20-21Downgrade Cantor Fitzgerald Buy → Neutral $4
Mar-03-21Downgrade RBC Capital Mkts Outperform → Sector Perform $5
Dec-02-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-02-20Downgrade Citigroup Buy → Neutral $10 → $4
Sep-04-19Initiated RBC Capital Mkts Outperform $12
Apr-20-18Initiated Ladenburg Thalmann Buy $27
May-11-22 06:55AM  
May-10-22 08:00AM  
Apr-26-22 07:17AM  
Apr-08-22 08:00AM  
Mar-15-22 08:00AM  
Mar-07-22 01:06PM  
Mar-04-22 08:00AM  
Feb-28-22 01:51PM  
Feb-08-22 08:00AM  
Jan-04-22 08:01AM  
Jan-03-22 07:25AM  
06:30AM  
Nov-10-21 08:30AM  
Nov-05-21 12:03PM  
Oct-07-21 08:30AM  
Sep-07-21 08:00AM  
Sep-06-21 12:58PM  
Aug-16-21 08:00AM  
Jul-08-21 04:30PM  
Jul-07-21 08:00AM  
Jul-06-21 07:01AM  
Jun-04-21 08:00AM  
May-26-21 08:00AM  
May-24-21 07:52AM  
May-21-21 08:46AM  
May-20-21 09:29AM  
May-13-21 04:05PM  
May-12-21 08:00AM  
May-07-21 08:42AM  
Apr-30-21 11:37AM  
Apr-20-21 08:00AM  
Apr-19-21 09:16AM  
08:00AM  
Mar-30-21 08:00AM  
Mar-20-21 04:51AM  
Mar-16-21 08:39AM  
Mar-15-21 08:00AM  
Mar-10-21 03:44AM  
Mar-03-21 07:46AM  
07:40AM  
07:00AM  
07:00AM  
Jan-15-21 02:22AM  
Dec-16-20 07:00AM  
12:30AM  
Dec-02-20 11:38AM  
11:30AM  
09:52AM  
07:35AM  
Dec-01-20 04:52PM  
Nov-25-20 08:51AM  
Nov-23-20 04:01PM  
Nov-16-20 06:07AM  
12:07AM  
Nov-12-20 04:10PM  
Oct-14-20 07:00AM  
Oct-12-20 07:00AM  
Oct-05-20 05:30AM  
Sep-30-20 08:00AM  
Sep-11-20 08:00AM  
Aug-25-20 07:50AM  
07:00AM  
07:00AM  
Aug-10-20 08:00AM  
Aug-05-20 09:00AM  
Jul-25-20 09:10AM  
Jul-23-20 07:00AM  
Jul-14-20 06:35AM  
Jul-13-20 09:00AM  
07:35AM  
07:00AM  
Jul-08-20 09:20PM  
Jun-29-20 08:00AM  
Jun-25-20 08:58AM  
Jun-22-20 09:02AM  
Jun-19-20 08:00AM  
Jun-11-20 08:00AM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-12-20 08:00AM  
May-07-20 08:00AM  
07:30AM  
Apr-22-20 11:50AM  
Apr-09-20 10:08AM  
Mar-30-20 08:00AM  
Mar-11-20 08:00AM  
Mar-05-20 04:06PM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Jan-23-20 06:00PM  
Jan-21-20 05:09PM  
Jan-10-20 11:43AM  
Jan-07-20 08:00AM  
Dec-19-19 10:20PM  
Dec-06-19 01:13PM  
Nov-26-19 08:00AM  
Nov-18-19 04:05PM  
Nov-08-19 08:00AM  
Nov-01-19 08:00AM  
Oct-16-19 07:01AM  
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rakhit AmitPresident and CMOJul 14Option Exercise1.8934,01764,292760,840Jul 16 06:21 PM
Rakhit AmitPresident and CMOJul 14Sale3.7134,017126,203726,823Jul 16 06:21 PM